news Collaboration to identify novel COVID-19 drug targets announced 30 April 2020 | By Hannah Balfour (Drug Target Review) Bringing together protein science, drug discovery experience and innovative technology, a new collaboration aims to identify novel drug targets for COVID-19.
news Antibodies developed from llama show promise in fighting COVID-19 30 April 2020 | By Victoria Rees (Drug Target Review) Engineering antibodies found in a llama, researchers have developed a potential COVID-19 therapy which they say can neutralise SARS-CoV-2.
article Developing respiratory therapeutics for prophylaxis and treatment 30 April 2020 | By Hannah Balfour (Drug Target Review) Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
news AI platform developed to rapidly identify treatment regimens for infections, including COVID-19 29 April 2020 | By Victoria Rees (Drug Target Review) A new AI tool has been created by researchers to identify the best treatment courses and doses for bacterial or viral infections, such as COVID-19.
news NIAID releases strategic plan, outlining COVID-19 research priorities 28 April 2020 | By Hannah Balfour (Drug Target Review) The US National Institute of Allergy and Infectious Diseases (NIAID) plan outlines four research priorities, including furthering understanding of SARS-CoV-2 viral transmission and pathogenesis and development of animal models.
article Cytokine storms: a major killer in patients with severe COVID-19 infection 27 April 2020 | By Professor Saad Shakir (Drug Safety Research Unit) Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
news Cell types enabling initial COVID-19 infection identified by researchers 27 April 2020 | By Victoria Rees (Drug Target Review) An international group of researchers has revealed that goblet and ciliated cells in the nose have high levels of the entry proteins for the SARS-CoV-2 coronavirus.
news Hyperferritinaemia could be causing severe COVID-19 27 April 2020 | By Hannah Balfour (Drug Target Review) Professor Yehuda Shoenfeld suggests hyperferritinaemia, a condition caused by high ferritin levels, may be causing the severe COVID-19 symptoms.
article Natural peptides versus COVID-19 25 April 2020 | By Oleg Kit (Interregional Academy of Personnel Management), Yuriy Kit (National Academy of Science of Ukraine) Peptides could serve as a potential platform for development of novel drugs for the treatment of the COVID-19 coronavirus.
article Histone deacetylase 2 (HDAC2) regulates pathological response of inflammatory monocytes: a potential target of adjuvant therapies for COVID-19 infection 23 April 2020 | By Dr Rosa Tordera (University of Navarra), Maria Cortes (University of Navarra) Histone deacetylase 2 (HDAC2) plays a key role in the regulation of inflammatory response in monocytes so could be a target for COVID-19, argue Dr Rosa Maria Tordera and Maria Cortes.
news Fundamental molecular research underpins our ability to combat COVD-19, says article 23 April 2020 | By Hannah Balfour (Drug Target Review) Ali Shilatifard’s article explains how investment in institutes performing molecular research is essential, as it is the foundation for all attempts to combat COVID-19 and other future pandemics.
news Lead SARS-CoV-2 inhibitor compound identified by researchers to treat COVID-19 23 April 2020 | By Victoria Rees (Drug Target Review) Researchers have found a lead compound which they say inhibits SARS-CoV-2 viral replication and demonstrates good pharmacokinetic activity in vivo.
news Could T-cell immunotherapy be the answer to COVID-19? 22 April 2020 | By Victoria Rees (Drug Target Review) Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
news COVID-19 research indicates SARS-CoV-2 exploits immune defences to drive infection 22 April 2020 | By Hannah Balfour (Drug Target Review) A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
news Glycomimetics could prevent COVID-19 from infecting human cells 21 April 2020 | By Hannah Balfour (Drug Target Review) Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
